The nation of Zimbabwe has turned down a significant US health deal worth 367 million US dollars (£272m) spanning five years over the United States' insistence on confidential data.
The decision became public after a government memo dated December was leaked, which showed President Emmerson Mnangagwa felt the arrangement was "lopsided".
A government spokesperson has since clarified that the United States was demanding access to genetic material for scientific study and commercial purposes but was unwilling to share the benefits from any future vaccines.
"We must now begin the difficult and regrettable task of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for continued talks to find a deal acceptable to all parties so the nation's critical HIV treatment initiative can continue.
Wider Background
Zimbabwe's decision comes after a similar case in Kenya, where a high court blocked a similar health funding agreement after legal challenges were filed about the security of citizens' health data.
Since resuming office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump stated its spending was "wasteful" and his administration was seeking direct bilateral deals to boost openness and responsibility.
As per statements, 16 African countries have so far agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Details of the Rejected Agreement
The funds for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration could have provided immense benefits for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information over an extended period, without any corresponding guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"Effectively, our country would supply the basic resources for scientific discovery with no certainty that the end products would be accessible to our population if a future pandemic arise."
National Interest and International Frameworks
He also said that the US's withdrawal from the global health body and its push of one-on-one health agreements were disrupting structures previously set up through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to manage potential global health emergencies.
"This system is intended to ensure that when a nation contributes its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to develop them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," he added.
"We are open to further dialogue with our American counterparts on how future co-operation might be designed in a manner that respects the independence and interests of each country."
Medical Community Response
Medical experts stated it recognised the official position, but recommended that talks need to persist considering much of the nation's HIV programmes were funded by foreign aid.
"Where specific concerns exist, including those relating to data governance or agreement terms, these can frequently be addressed via technical clarification and mutually agreed protections," the group said.
The situation emphasises the ongoing challenges between receiving much-needed international aid and safeguarding a country's data in an increasingly interconnected world.